News Releases
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
April 17, 2020
-
March 16, 2020- Top-Line Data from Phase 2 EMPhASIS Trial in Relapsing-Remitting Multiple Sclerosis Expected in Third Quarter 2020 -
-
January 8, 2020Phase 1 Clinical Studies to begin in First Half of 2020
-
December 4, 2019IMU-856 has the potential to address one of the putative root causes of inflammatory bowel disease without impairing the immune system
-
October 10, 2019- Milestone Achieved Nine Months Ahead of Initial Schedule; Top-Line Data Expected in Q3 2020 -
-
September 11, 2019Preclinical Findings Confirm Favorable Profile of IMU-838 as Compared to Teriflunomide in the Potential Treatment of Relapsing-Remitting Multiple Sclerosis
-
September 5, 2019- Unblinded Data Review Committee Recommended Continuation of the Lowest, 10 mg Dose as well as the Highest, 45 mg Dose -
-
August 12, 2019- Study Being Conducted in Collaboration with Investigators at Arizona State University and the Mayo Clinic -
-
June 21, 2019- Phase 2 Trial in Relapsing-Remitting Multiple Sclerosis Expected to be the First Efficacy Read-Out of IMU‑838; Top-line Data Anticipated in Q3 2020 -
-
June 4, 2019- Results confirm IMU-935 as a potent inverse agonist of RORϒt with an IC50 of 24 nM, leading to potent inhibition of Th17 differentiation while allowing normal thymocyte maturation -
-
April 12, 2019- Developing Oral Therapies with Best-in-Class Potential -
-
March 27, 2019Of the Votes Received to Date, More than 98% are Voting in Favor of the Business Combination
-
March 4, 2019
-
January 7, 2019Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets
-
November 5, 2018Immunic AG gains exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel disease
-
April 26, 2018First patient with ulcerative colitis entered the ‘CALDOSE-1’ trial with Immunic’s oral investigational drug IMU-838, a best-in-class DHODH inhibitor
-
January 11, 2018FDA has granted IND approval for Immunic’s oral investigational drug IMU-838
-
December 12, 2017Two phase 1 studies for IMU-838 in healthy volunteers have been completed
-
September 5, 2017Omega and Fund+ broaden Immunic’s investor base and add an additional EUR 10 million (USD 12 million) in equity financing
-
February 1, 2017Series A financing round extended to EUR 21.7 Million